Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $38.67 down -0.13% from its previous closing price of $38.72. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 1.21 million shares were traded. CYTK stock price reached its highest trading level at $39.0955 during the session, while it also had its lowest trading level at $37.79.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.76 and its Current Ratio is at 6.76.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’25 when Blum Robert I sold 5,000 shares for $38.42 per share. The transaction valued at 192,100 led to the insider holds 383,108 shares of the business.
Malik Fady Ibraham sold 2,000 shares of CYTK for $72,680 on Aug 05 ’25. The EVP Research & Development now owns 140,610 shares after completing the transaction at $36.34 per share. On Jul 29 ’25, another insider, Blum Robert I, who serves as the President & CEO of the company, sold 5,000 shares for $36.45 each. As a result, the insider received 182,250 and left with 388,108 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4627136000 and an Enterprise Value of 4760765440. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.97. Its current Enterprise Value per Revenue stands at 55.527 whereas that against EBITDA is -8.856.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.63, which has changed by -0.31509036 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $59.39, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 9.58%, while the 200-Day Moving Average is calculated to be -8.03%.
Shares Statistics:
For the past three months, CYTK has traded an average of 1.47M shares per day and 1657480 over the past ten days. A total of 119.60M shares are outstanding, with a floating share count of 117.00M. Insiders hold about 2.20% of the company’s shares, while institutions hold 114.38% stake in the company. Shares short for CYTK as of 1753920000 were 15520330 with a Short Ratio of 10.56, compared to 1751241600 on 15020046. Therefore, it implies a Short% of Shares Outstanding of 15520330 and a Short% of Float of 16.919999999999998.
